ZE74-0282

N/A

Report date: 2026/05/15 20:01:45
NMEFirst In Class

Base Information

Drug NameZE74-0282
Drug Alias NameZE74-0282
ClassificationSmall molecules
Mechanisms of ActionJAK2 V617F inhibitors
TargetsJAK2 V617F
Therapy Area/IndicationsPrimary MyelofibrosisMyeloproliferative DisordersPolycythemia Vera
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEilean Therapeutics LLC
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsPrimary MyelofibrosisMyeloproliferative DisordersPolycythemia Vera
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A